Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY |
| 3 |
| Oct 2, 2024 |
| clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06475326 | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 87 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06387810 | Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer(undetermined) | unknown | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05832892 | Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 41 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06018896 | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer(PTCA199-4) | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06422156 | SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer(Nim-PC-28) | unknown | Phase 2 | 73 | Peking University Third HospitalOTHER | 0 | May 20, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04672005 | Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer | unknown | Phase 2 | 30 | Lyudmyla BerimOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06404840 | Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06405685 | Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06078787 | Olaparib in PALB2 Advanced Pancreatic Cancer(PALBOLA) | unknown | Phase 2 | 16 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04298008 | AZD6738 Plus Durvalumab in Biliary Tract Cancer | unknown | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04298021 | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | unknown | Phase 2 | 74 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04371224 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer(NaliCap) | unknown | Phase 2 | 200 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04447092 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | unknown | Phase 2 | 77 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06233864 | A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06353581 | Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX | unknown | Phase 2 | 78 | Yonsei UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05064618 | Investigator-initiated Clinical Trial of MIKE-1(MIKE-1) | unknown | Phase 1 / Phase 2 | 55 | Nagoya UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03721744 | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 336 | 1Globe Health Institute LLCINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT06345300 | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study | unknown | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05371223 | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases(Nab-PIPAC) | unknown | Phase 2 | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT04151277 | PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer | unknown | Phase 2 | 500 | Judith Dixon-HughesOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06202014 | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT04617457 | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas(HOLIPANC) | unknown | Phase 2 | 150 | University of CologneOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06153368 | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05580445 | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 114 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06134765 | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | unknown | Phase 2 | 89 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05363007 | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma(SINAI) | unknown | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 22, 2024source: clinicaltrials